Precision oncology based on omics data: The NCT Heidelberg experience

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

(2017) Malachi Griffith et al.   NATURE GENETICS

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

(2016) Andrea Casadei Gardini et al.   BMC CANCER

Modeling Development and Disease with Organoids

(2016) Hans Clevers   CELL

Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma

(2016) Priya Chudasama et al.   CLINICAL CANCER RESEARCH

Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology

(2016) Moritz Jesinghaus et al.   GENES CHROMOSOMES & CANCER

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

(2016) Fabrice André et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFRgene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis

(2016) Xin Zhang et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Omics Profiling in Precision Oncology

(2016) Kun-Hsing Yu et al.   MOLECULAR & CELLULAR PROTEOMICS

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

(2016) M. Schwaederle et al.   MOLECULAR CANCER THERAPEUTICS

The tumour trail left in blood

(2016) Kelly Rae Chi   NATURE

What have we learned from SHIVA?

(2016) Christophe Le Tourneau et al.   Nature Reviews Clinical Oncology

Seamless Oncology-Drug Development

(2016) Tatiana M. Prowell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dauerhafte Remission unter dualer HER2-Blockade mit Trastuzumab und Pertuzumab bei metastasiertem Gallenblasenkarzinom

(2016) E. Czink et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation

(2015) María Sereno et al.   ANTI-CANCER DRUGS

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

(2015) C. Krepler et al.   CLINICAL CANCER RESEARCH

High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer

(2015) Nicole Pfarr et al.   GENES CHROMOSOMES & CANCER

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

(2015) Sue Richards et al.   GENETICS IN MEDICINE

Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

(2015) Ariel Lopez-Chavez et al.   JOURNAL OF CLINICAL ONCOLOGY

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

N-of-1 trials in oncology

(2015) Laurence Collette et al.   LANCET ONCOLOGY

Precision medicine: lessons learned from the SHIVA trial

(2015) Apostolia M Tsimberidou et al.   LANCET ONCOLOGY

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

(2015) Christophe Le Tourneau et al.   LANCET ONCOLOGY

Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling

(2015) M Kordes et al.   LEUKEMIA

Patient-centric trials for therapeutic development in precision oncology

(2015) Andrew V. Biankin et al.   NATURE

Personalized medicine: Time for one-person trials

(2015) Nicholas J. Schork   NATURE

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

So rare we need to hunt for them: reframing the ethical debate on incidental findings

(2015) Sebastian Schuol et al.   Genome Medicine

Patient-derived xenografts for individualized care in advanced sarcoma

(2014) Justin Stebbing et al.   CANCER

Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

(2014) E. Garralda et al.   CLINICAL CANCER RESEARCH

Physicians' Attitudes About Multiplex Tumor Genomic Testing

(2014) Stacy W. Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report

(2014) Rehan Akbani et al.   MOLECULAR & CELLULAR PROTEOMICS

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution

(2014) Peter Eirew et al.   NATURE

Sequencing depth and coverage: key considerations in genomic analyses

(2014) David Sims et al.   NATURE REVIEWS GENETICS

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Lessons from the Cancer Genome

(2013) Levi A. Garraway et al.   CELL

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing

(2013) Robert C. Green et al.   GENETICS IN MEDICINE

Designing Transformative Clinical Trials in the Cancer Genome Era

(2013) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping

(2012) J. D. Wulfkuhle et al.   CLINICAL CANCER RESEARCH

A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping

(2012) Angela Zupa et al.   Journal of Thoracic Oncology

Dissecting the genomic complexity underlying medulloblastoma

(2012) David T. W. Jones et al.   NATURE

Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

(2011) S. Roychowdhury et al.   Science Translational Medicine

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

(2011) Peter S. Hammerman et al.   Cancer Discovery

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

(2010) I. J. Dahabreh et al.   ANNALS OF ONCOLOGY

Reverse phase protein microarrays advance to use in clinical trials

(2010) Claudius Mueller et al.   Molecular Oncology

Translating cancer research into targeted therapeutics

(2010) J. S. de Bono et al.   NATURE

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification

(2010) Jan C Brase et al.   Proteome Science